Royalty Pharma
RPRX | NASDAQ
$58.44
+$0.03 (+0.05%)
At close: Sep 21, 2026, 4:00 PM ET
$58.44
$0 (0.00%)
Pre-market:
Sep 22, 2026, 4:00 AM ET
Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Pablo Legorreta | Founder, Chairman of the Board & Chief Executive Officer |
| Eric Cornelius Schneider | Senior Vice President & Chief Technology Officer |
| Terrance Coyne | Executive Vice President & Chief Financial Officer |
| Arthur Richard McGivern | Executive Vice President of Investments & Chief Scientific Officer |
| Christopher Hite | Chairman of Partnering & Investments |
| George Grofik | Senior Vice President and Head of Investor Relations & Communications |
| Greg Butz | Executive Vice President of Partnering & Investments |
| James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer |
| Marshall Urist | Head of Research & Investments |
| Molly Sawaya | Executive Vice President & Head of Human Capital |
| Sandy Balkin | Senior Vice President of Strategy & Analytics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2026 | 4 | Filing |
| Aug 17, 2026 | SC 13D/A | [Amend] Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | 13F-NT | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
Royalty Pharma
| Country | United States |
| IPO Date | Jun 15, 2020 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Pablo Legorreta |
Contact Details
110 East 59th Street New York,
New York 10022 United States
Stock Details
| Ticker Symbol | RPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001802768 |
| CUSIP Number | G7709Q104 |
| ISIN Number | GB00BMVP7Y09 |
| SIC Code | 2834 |
Recent News
- 6 days ago / globenewswire.comRoyalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
- 8 days ago / seekingalpha.comRoyalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 13 days ago / globenewswire.comRoyalty Pharma to present at upcoming investor conferences
- 27 days ago / seekingalpha.comRoyalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating
- 27 days ago / seekingalpha.comRoyalty Pharma: The Quiet Compounder The Market Is Still Mispricing
- 1 month ago / zacks.comRoyalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
- 1 month ago / globenewswire.comRoyalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
- 2 months ago / marketbeat.comRoyalty Pharma Q2 Earnings Call Highlights
- 2 months ago / seekingalpha.comRoyalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.comRoyalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Add to Watchlist
Select watchlists to add or remove RPRX